Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Non-Current Debt: 2018-2025

Historic Non-Current Debt for Abeona Therapeutics (ABEO) over the last 4 years, with Sep 2025 value amounting to $10.9 million.

  • Abeona Therapeutics' Non-Current Debt fell 23.54% to $10.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.9 million, marking a year-over-year decrease of 23.54%. This contributed to the annual value of $13.0 million for FY2024, which is N/A change from last year.
  • As of Q3 2025, Abeona Therapeutics' Non-Current Debt stood at $10.9 million, which was down 22.44% from $14.0 million recorded in Q2 2025.
  • Abeona Therapeutics' 5-year Non-Current Debt high stood at $18.1 million for Q1 2024, and its period low was $1.2 million during Q1 2021.
  • Over the past 2 years, Abeona Therapeutics' median Non-Current Debt value was $14.0 million (recorded in 2025), while the average stood at $13.9 million.
  • Over the last 5 years, Abeona Therapeutics' Non-Current Debt had its largest YoY gain of 224.15% in 2022, and its largest YoY loss of 51.39% in 2022.
  • Quarterly analysis of 4 years shows Abeona Therapeutics' Non-Current Debt stood at $3.8 million in 2021, then rose by 8.75% to $4.2 million in 2022, then reached $13.0 million in 2024, then fell by 23.54% to $10.9 million in 2025.
  • Its Non-Current Debt stands at $10.9 million for Q3 2025, versus $14.0 million for Q2 2025 and $11.1 million for Q1 2025.